VIA EDGAR

U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549-3720

Attention: Jane Park

Re: Aadi Bioscience, Inc. Registration Statement on Form S-3 File No. 333-259785

> Acceleration Request Requested Date: October 1, 2021 Requested Time: 4:00 P.M. Eastern Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Aadi Bioscience, Inc. (the "**Company**") hereby requests that the abovereferenced Registration Statement on Form S-3 (File No. 333-259785) (the "**Registration Statement**") be declared effective at the "Requested Date" and "Requested Time" set forth above, or as soon thereafter as practicable, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission. Once the Registration Statement has been declared effective, please confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Dan Koeppen at (858) 350-2393 or via email at dkoeppen@wsgr.com.

[Signature page follows]

Securities and Exchange Commission September 30, 2021 Page 2

Sincerely,

AADI BIOSCIENCE, INC.

/s/ Neil Desai

Neil Desai President and Chief Executive Officer

cc: Dan Koeppen, Wilson Sonsini Goodrich & Rosati, P.C. Robert L. Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C. Savir S. Punia, Wilson Sonsini Goodrich & Rosati, P.C.